Fri, 20 Dec 2024 18:30:02 GMT
Novo Nordisk tumbles
Novo Nordisk said Friday that its obesity drug, CagriSema, helped patients lose 22.7% of their weight in a trial, less than the expected 25%. This caused its market value to drop by up to $125 billion.